Bradsher Neal C 4
4 · STAAR SURGICAL CO · Filed Mar 10, 2026
Research Summary
AI-generated summary of this filing
STAAR Surgical (STAA) Director Neal Bradsher Receives 7,524-Share Option Award
What Happened
Neal C. Bradsher, a director and 10% owner of STAAR Surgical Company (STAA), received an award of 7,524 derivative securities on March 6, 2026. The Form 4 reports the grant as an acquisition (code A) at $0.00 — i.e., a grant of stock options/awards as compensation rather than a cash purchase or sale. No exercise or sale occurred in this filing.
Key Details
- Transaction date: March 6, 2026; Form 4 filed March 10, 2026. (No late-filing flag provided in the excerpt.)
- Transaction type: Grant/Award of derivative securities (options); reported price $0.00 (grant, not purchase).
- Number of options granted: 7,524.
- Shares/options owned after the transaction: Not specified in the provided filing excerpt.
- Footnotes:
- F1: Options vest and become exercisable on the earlier of (a) June 18, 2026 or (b) the Issuer’s 2026 annual meeting, subject to continuous service.
- F2: Options were granted as director compensation under the Issuer’s Amended and Restated Omnibus Equity Incentive Plan.
Context
This is a compensation grant to a director (and 10% owner), a routine corporate practice to compensate board members. It is an award of options (a derivative); there was no immediate exercise or sale reported. Such grants reflect compensation policy more than an insider trading signal — purchases or sales by insiders typically convey stronger trading intent.
Insider Transaction Report
- Award
OPTION TO PURCHASE COMMON STOCK
[F2][F1]2026-03-06+7,524→ 7,524 totalExercise: $18.46Exp: 2036-03-05→ COMMON STOCK (7,524 underlying)
Footnotes (2)
- [F1]These options will vest and become exercisable on the earlier of: (a) June 18, 2026 and (b) the date of STAAR Surgical Company's (the "Issuer") 2026 annual meeting of shareholders, subject, in each case, to Neal C. Bradsher's (the "Reporting Person") continuous service with the Issuer.
- [F2]These options were granted to the Reporting Person by the Issuer on March 6, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended.